- Home
- SAND vs BCRX Comparison
SAND vs BCRX Comparison
Compare SAND & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAND
- BCRX
- Stock Information
- Founded
- SAND 2007
- BCRX 1986
- Country
- SAND Canada
- BCRX United States
- Employees
- SAND N/A
- BCRX N/A
- Industry
- SAND
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAND
- BCRX Health Care
- Exchange
- SAND NYSE
- BCRX Nasdaq
- Market Cap
- SAND 1.9B
- BCRX 1.7B
- IPO Year
- SAND N/A
- BCRX 1994
- Fundamental
- Price
- SAND $7.49
- BCRX $7.25
- Analyst Decision
- SAND Buy
- BCRX Buy
- Analyst Count
- SAND 3
- BCRX 6
- Target Price
- SAND $9.42
- BCRX $15.67
- AVG Volume (30 Days)
- SAND 4.2M
- BCRX 3.2M
- Earning Date
- SAND 05-01-2025
- BCRX 05-05-2025
- Dividend Yield
- SAND 0.70%
- BCRX N/A
- EPS Growth
- SAND N/A
- BCRX N/A
- EPS
- SAND 0.05
- BCRX N/A
- Revenue
- SAND $176,283,000.00
- BCRX $450,712,000.00
- Revenue This Year
- SAND $12.83
- BCRX $27.66
- Revenue Next Year
- SAND $12.67
- BCRX $13.59
- P/E Ratio
- SAND $155.90
- BCRX N/A
- Revenue Growth
- SAND N/A
- BCRX 36.00
- 52 Week Low
- SAND $4.92
- BCRX $4.03
- 52 Week High
- SAND $7.74
- BCRX $9.50
- Technical
- Relative Strength Index (RSI)
- SAND 70.99
- BCRX 34.85
- Support Level
- SAND $7.37
- BCRX $7.44
- Resistance Level
- SAND $7.74
- BCRX $7.93
- Average True Range (ATR)
- SAND 0.21
- BCRX 0.25
- MACD
- SAND 0.08
- BCRX -0.02
- Stochastic Oscillator
- SAND 82.29
- BCRX 3.33
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.